NPM1 and acute myeloid leukemia: In a survival analysis of 25 patients affected with NPM1-mutated AML, Greiner et al., documented a better overall survival (OS) in patients experiencing autologous specific T-cell responses against one or two immunogenic NPM1-mutated epitopes, namely peptides #1 and #3, compared to cases showing no specific immune responses, suggesting that immunity against the mutated region of NPM1 protein may potentially contribute to the globally favorable outcome of NPM1-mutated AML patients [27].